Human immunodeficiency virus type 1 subtype C (HIV-1C) accounts for about 50% of all HIV infections in the pandemic and is the predominant subtype in the heavily burdened region of southern Africa. HIV-1C possesses unique genetic and phenotypic features that might be associated with biological differences compared to other subtypes. Here, we generated virus isolates from individuals at different stages of HIV-1C infection and investigated the chemokine receptor repertoire that the derived HIV-1C isolates may utilize for entry. Our results show that the R5 phenotype predominates among viruses in Botswana, with a lesser contribution of viruses showing the dualtropic X4R5 phenotype. No viruses of pure X4 phenotype were found, which suggests no discernable evolution of HIV-1C to a monotropic X4 phenotype as the epidemic ages in Botswana. Usage of other coreceptors was rare and apparently insignificant. These results enhance our understanding of HIV-1C biology, with implications for designing and testing therapeutic and prophylactic agents. D
Introduction
In most countries in southern Africa, HIV-1 prevalence rates exceed 20% in the adult population (UNAIDS, 2002) . HIV-1C is the predominant HIV-1 genotype in southern Africa (Novitsky et al., 2002; Ping et al., 1999; Williamson et al., 2003) , and the epidemic in this region is characterized by a relatively high level of intrasubtype diversity (Choudhury et al., 2000; Novitsky et al., 1999; van Harmelen et al., 2001) . HIV-1C is also the predominant and most rapidly spreading HIV-1 subtype in the world (Esparza and Bhamarapravati, 2000; Essex, 1999; Osmanov et al., 2002) . Comparative studies of the role of HIV-1 subtypes in transmission and disease pathogenesis have been difficult to undertake because there are few regions where multiple subtypes coexist at sufficiently high levels to allow informative population-based studies. However, in east Africa, where subtypes A, C, D, and their recombinants co-circulate at relatively high levels, some studies have suggested significant differences between subtype C and other subtypes. In Kenya, a cross-sectional study showed that women infected with HIV-1C had significantly lower CD4 cell counts and higher plasma RNA levels than those infected with subtypes A or D (Neilson et al., 1999) .
It has also been reported that, in Tanzania, HIV-1C appears to have been introduced after subtypes A and D were already established and HIV-1C quickly became one of the major subtypes while subtype D appears to have declined in Dar es Salaam (Renjifo et al., 1998) . In a mother-to-child transmission cohort, it was observed that mothers infected with subtype C and intersubtype recombinants were significantly more likely to transmit the virus to their infants compared to those infected with subtype D viruses (Blackard et al., 2001; Renjifo et al., 2001) . In addition, HIV-1C showed preferential transmission in utero when compared to HIV-1A or HIV-1D in the same cohort (Renjifo et al., 2004) . Furthermore, in A -D and C -D recombinant genomes, the V3 region of subtype A or C was preferentially selected, suggesting reduced fitness of subtype D V3 with respect to V3 from subtype A or C . These epidemiological and observational studies provide clues to subtype-specific differences and suggest that HIV-1C in particular may be unique in its spread and natural history, but they fail to provide answers to the mechanisms that may underlie the differences.
Virological factors may be at least partially responsible for the rapid expansion and predominance of HIV-1C in southern Africa and elsewhere. Studies have shown, for example, that HIV-1C in Africa usually possesses an extra copy of the NF-nB enhancer element in the long terminal repeat (LTR) region (Gao et al., 1996; Montano et al., 1997; Salminen et al., 1996) , which may be associated with an increased responsiveness to activation by cellular proteins and proinflammatory cytokines (Jeeninga et al., 2000; Montano et al., 1997 Montano et al., , 2000 Naghavi et al., 1999) . In addition, utilization of coreceptors other than CCR5 is rare for HIV-1C (Bjorndal et al., 1999; Cecilia et al., 2000; Tscherning et al., 1998) , although the implications of this observation on transmission and pathogenesis of HIV-1C remain undetermined. The observation that HIV-1C viruses predominantly use CCR5 (R5 phenotype) as the major coreceptor for entry into cells even in late stages of disease is intriguing because, in approximately 50% of HIV-1 subtype B infections, progression to AIDS is associated with development of viral variants that utilize CXCR4 (X4 phenotype) as coreceptor (Kuiken et al., 1992; Schuitemaker et al., 1992; Tersmette et al., 1989a) . This change in viral phenotype from R5 to X4 has also been frequently observed for other major non-B HIV subtypes and recombinants (Bjorndal et al., 1997; De Wolf et al., 1994; Kato et al., 1999; Tscherning et al., 1998; Vergne et al., 2003) , suggesting that HIV-1C is unique in maintaining its predominant CCR5 tropism throughout infection.
Early studies showed that HIV-1C viruses display low-level replication kinetics in macrophages followed by a nonproductive stage from which virus could be rescued by co-cultivation with Jurkat tat cells (Bjorndal et al., 1999) . Recently, it has been suggested that CCR5-tropic HIV-1C viruses have an attenuated phenotype compared to their subtype B counterparts when propagated in CD4+ lymphocytes and macrophages (Ball et al., 2003; Pollakis et al., 2004) . These studies further show that the restriction to virus replication observed for HIV-1C viruses is at the level of virus entry via the CCR5 coreceptor. The in vitro studies suggest uniqueness of HIV-1C in the global epidemic and have led to speculation that the apparent attenuation of HIV-1C may be responsible for its success as the predominant subtype in the pandemic.
In earlier studies in Botswana, we demonstrated that nonrecombinant HIV-1C is the predominant genotype, and we have undertaken detailed phylogenetic analysis and have identified various intrasubtype lineages based on near full-length genome analysis of HIV-1C (Novitsky et al., 1999 (Novitsky et al., , 2002 . We have generated infectious and non-infectious clones of the virus to facilitate detailed genetic analysis . However, while genotypic data are clearly important in tracking the changing population dynamics of an epidemic as well as in designing appropriate therapeutic and prophylactic interventions, it is not always possible to predict viral phenotype from genotypic data. In the present study, therefore, we sought to study the efficiency of generating viral isolates and the extent of coreceptor usage by primary viral isolates from individuals at different stages of infection, all assessed in relation to clinical staging or CD4 cell count. Specifically, we addressed whether there is a trend towards CXCR4-only or other coreceptor tropism for HIV-1C isolates from Botswana as the epidemic matures, in light of a number of recent reports suggesting such a trend in other countries Johnston et al., 2003; Papathanasopoulos et al., 2002; van Rensburg et al., 2002) . We analyzed subtype C viruses isolated from Botswana in 1996 and in 2003. We reasoned that, if there is a changing coreceptor usage profile for HIV-1C, isolates from later years might show a greater tendency towards CXCR4-tropism, assuming similar stages of disease progression. We also assessed the reliability of V3 loop sequence-based methods in predicting coreceptor usage for HIV-1C.
Results

Samples
The 1996 samples described here were from anonymous donors from Botswana, and details on HIV testing, sample collection, peripheral blood mononuclear cell (PBMC) isolation, and the relevant study information were described previously Novitsky et al., 2001) . At the time, CD4+ cell count and viral load quantification were not available in Botswana. Age, gender, clinical manifestation, and disease staging information were available. Patient clinical classification was carried out according to the 1987 Centers for Disease Control and Prevention (CDC) revised criteria (CDC, 1987) . The 1996 viral isolates were propagated in PBMCs from anonymous HIV-negative donors from North America (as opposed to the 2003 samples where PBMCs from Botswana blood donors were used). Details on viral load, CD4 cell count, viral isolation, and envelope gene sequencing are summarized in Table 1 .
HIV-1C isolation
Eleven viruses were isolated from PBMC obtained from two asymptomatic and nine symptomatic HIV-1-positive donors in Botswana in 1996 (Novitsky et al., 1999 (Novitsky et al., , 2002 . For the 2003 samples, viral isolation was attempted from PBMC or plasma from forty-two HIV-infected individuals. The CD4 cell count for this study population ranged from 10 to 1047 cells/Al with a mean of 220 and a median of 166. Twenty-eight of the fortytwo (66.7%) PBMC source individuals had CD4 cell counts less than 200 cells/Al, indicating that they were in late stages of disease. The log 10 plasma viral load ranged from less than 2.6 to greater than 5.9 with a median of 5.1 and a mean of 4.9. Four study participants had undetectable HIV-1 viral load despite relatively low CD4 cell count, which is not an uncommon observation in Botswana. Of the 42 samples analyzed, 29 yielded viral isolates, representing an isolation success rate of 69%. Twenty-one isolates were generated from the 28 samples with CD4 count less than 200, representing an isolation success rate of 75%, while 7 isolates were obtained from the 13 samples with CD4 cell count above 200, which is equivalent to a success rate of 53.8%. CD4 cell count was unavailable for 1 sample from which an isolate was obtained. A chi-square test was used to assess whether the ability to isolate the virus is associated with the level of CD4 cell count. For this purpose, CD4 count equal to or less than 200 was considered low, while CD4 count greater than 200 was considered high. Isolation was not associated with the CD4 level (chi-square = 1.83, P = 0.18; Fisher's Exact P = 0.28).
The growth characteristics in PBMCs for the viruses detected in the 2003 samples are summarized in Table 2 . Statistical tests were done to examine differences between the CD4 cell counts, viral load, and the growth pattern in vitro of the samples as described in Tables 2 and 3 . There was a significant negative linear relation between CD4 and plasma viral load (Spearman rank order correlation, r s = À0.54126; P < 0.001).
Determination of coreceptor usage
Although several studies have suggested that HIV-1C viruses may be unique in that variants that use coreceptors other than CCR5 may be very rare, a number of recent reports have suggested that CXCR4 utilizing variants are being encountered with greater frequency as the epidemic matures Johnston et al., 2003; Papathanasopoulos et al., 2002; van Rensburg et al., 2002) . CCR5 and CXCR4 are the main chemokine receptors utilized by most primary isolates of HIV-1 as coreceptors for cell entry, but some viral variants may use other coreceptors. Most studies have only investigated the ability of HIV-1C to use CXCR4 and CCR5, but we also asked whether HIV-1C may evolve to use some of the minor coreceptors. We therefore decided to characterize the isolated subtype C viruses for the use of common chemokine receptors. We also compared the isolates from 1996 to those from 2003 to examine if there are discernable changes in coreceptor usage profile as the HIV-1C epidemic has aged in Botswana. In order to determine what coreceptors each of the viral isolates used to enter cells, U87.CD4 glioma cells expressing different coreceptors were infected with cell-free PBMC tissue culture supernatants. Table 3 shows the highest amounts of p24 antigen reached by the isolates over a 10-day culture period in U87.CD4 glioma cells expressing CCR1, CCR2(b), CCR3, CXCR4, or CCR5. All twenty-nine of the viruses studied from 1996 and 2003 that grew in any of these cells used CCR5 as a coreceptor for entry into cells. Two isolates (03BW6218 and 03BW4482) did not utilize any of the coreceptors tested and may require further investigation. Three viral isolates, 96BW17A09 from 1996 and 03BW.1102 and 03BW.1110 from 2003, used CXCR4 more efficiently than they did CCR5. None of the studied viruses used coreceptors other than CCR5 and CXCR4.
Six isolates, 96BW.0502, 96BW.1210, 96BWMO1.5, 96BWMO3.2, 03BW.6274, and 03BW.6360, appeared to use CXCR4, but with much less efficiency than they used CCR5 because they yielded more than 100 pg/ml of p24 antigen in U87.CD4.CXCR4 cell supernatant when propagated in these cells (Table 3 ). In order to confirm whether these isolates were truly dualtropic and in order to amplify replication of possible minor CXCR4-tropic variants within the isolates, we undertook two separate investigations. First, we passaged these six viral isolates and the three that used CXCR4 better than CCR5 (96BW17A09, 03BW.1102, and 03BW.1110) in U87.CD4. CXCR4 cells three times (data not shown). While isolates 96BW17A09, 03BW.1102, and 03BW.1110 showed robust replication at each passage, none of the other isolates replicated, and viral DNA could be amplified from thirdpassage cells for only the three isolates. Secondly, supernatants from all viral isolates were used to infect MT-2 cells, and the cells were checked for viral growth by monitoring syncytia induction and p24 antigen quantification in tissue culture fluid. Again, only isolates 96BW17A09, 03BW.1102, and 03BW.1110 showed extensive syncytia induction and p24 antigen production (data not shown). Isolate 03BW.6274 showed mild syncytia induction and low-level replication in MT-2 cells.
Genotypic analysis of env gene of HIV isolates
Our previous studies in Botswana have shown that HIV-1C viruses, which can be assigned to diverse phylogenetic lineages, dominate the HIV-1 epidemic in the country Novitsky et al., 1999 Novitsky et al., , 2002 , with sporadic detection of rare recombinants . However, in other high-prevalence countries, particularly in east Africa, the epidemic has rapidly evolved in recent years with introduction and expansion of new subtypes or of circulating recombinant forms (Hoelscher et al., 2002; Koulinska et al., 2001; Renjifo et al., 1998; Yang et al., 2004; Yirrell et al., 2002) . We investigated whether any such change could be observed at a later stage of the epidemic in Botswana. Phylogenetic analyses showed that sequences from samples obtained in 2003 clustered with subtype C references (Fig. 1) . The 2003 sequences were scattered across the subtype C branch and were not distinguished phylogenetically from sequences isolated between 1996 and 2000 in Botswana.
Although the near full-length genome analysis allowed us to identify intrasubtype lineages within HIV-1C, analysis of viral sequences at the gene or partial gene level resulted in fewer lineages supported by significant bootstrap values, demonstrat- 6 PBMCs from three donors were mixed and stimulated with PHA and IL-2 for 72 h prior to co-culture with 2 Â 10 6 HIV-1-infected PBMCs. The CCR5-utilizing molecular clones MJ4 and HXB2RU3CI, and the CXCR4-tropic HXB2RU3 were used as controls. All infections were followed by quantification of the p24 antigen by ELISA. For the controls, culture supernatant corresponding to 500 pg of p24 was used to infect 2 Â 10 6 cells. The following day, the target cells were washed three times with PBS and then new media was added.
ing clustering dependent on the analyzed sequence length (Novitsky et al., 2002) . Consistent with this observation, only 8 out of 13 Botswana lineages (including 3 partial lineages) were found in the current analysis of the region spanning 957 nucleotides of env. Five lineages that included 2 to 3 sequences were confirmed by significant bootstrap values, namely, lineages 5, 7, 9, 10, and 16 described in Novitsky et al. (2002) , while three more lineages (#3, #13, and # 15) included partial sequences that were seen in the near full-length analysis. Interestingly, two isolates from the 2003 set (03BW.1017 and 03BW.1103) formed a new lineage that was supported by a bootstrap value of 96. Sequences 03BW.1008 and 03BW.1796 clustered within previously described lineages with high bootstrap values, lineage 9 and 15, respectively. The pairwise evolutionary distances were similar within the subsets of 1996 -2000 (n = 54) and 2003 (n = 38) sequences with mean values of 14.4% and 15.7%, respectively.
A number of sequence-based methods, mostly dependent on V3 loop amino acids, are available for predicting coreceptor usage for HIV-1 viruses. In order to determine if the generated sequences from CXCR4-tropic viruses may have distinctive features associated with this phenotype, V3 loop sequences were aligned and are shown in Fig. 2 . The two most commonly used methods for predicting CXCR4 coreceptor usage are (i) the presence of basic amino acids at positions 11 and 25 of the V3 loop Fouchier et al., 1995) and (ii) an overall charge of the V3 loop equal to or greater than +5 (Fouchier et al., 1992) . Among the 3 viruses that favored CXCR4 usage, 2 had typical CXCR4-like features. 96BW17A09 had an overall V3 charge of +7 and a basic amino acid (arginine) residue at position 25. This sequence also had an insertion of 2 amino acids just upstream of the crown of the V3 loop. The V3 loop crown for this sample was an atypical GRGQ, in contrast to the GPGQ sequence most commonly encountered among subtype C. The overall V3 loop charge for 03BW.1102 was +6, with a basic amino acid at position 11. This sequence also had a subtype B-like GPGR crown sequence. The V3 loop sequence of the 03BW.1110 sample lacked a basic amino acid at either position 11 or 25, had an overall V3 charge of +4 and a typical GPGQ crown sequence. Samples 03BW.1110 and 03BW.1102 shared a basic amino acid substitution. Sample 03BW.6274, which might be classified as a weakly dualtropic phenotype because it used CXCR4 inefficiently and showed low level syncytia induction in MT-2 cells, had an atypical GPGA V3 loop crown and an overall V3 loop charge of less than +5 with no basic of p24 viral supernatants from PBMC co-cultures were used to infect U87.CD4 cells expressing different coreceptors. Cells were washed 3 times with PBS after 24 h, and fresh growth medium was added. Infection was followed by quantification of the p24 core protein by ELISA. Half the medium was sampled and replaced with fresh medium at days 4 and 7.
amino acid at either position 11 or 25. The CCR5-tropic isolate 96BWMO1.5 had a basic amino acid at position 10, a feature that was shared with the dualtropic 03BW.1102 and 03BW.1110. Sample 03BW.6360 had a basic amino acid (arginine) at position 28. All the other CCR5-utilizing viruses from 1996 and 2003 had features that are associated with R5-tropic V3 loop in subtype B infections. They all had an overall V3 loop charge of less than +5, lacked basic amino acids at position 11 or 25, and had the typical subtype C GPGQ crown sequence. We could not generate coreceptor usage data for 28 out of 61 (45.9%) samples in this study. This was because source PBMCs did not yield a viral isolate on co-culture (21 of 61, 34.4%) or growth in PBMC was so poor that we did not have enough supernatant to infect coreceptor expressing cells (9 of 29, 31.03%). Among these viruses for which coreceptor utilization determination was not done, 03BW.1081 had some unusual features. It had a high V3 loop charge of +9, the crown was an uncharacteristic GLRY, and there were other unusual insertions throughout the V3 loop (Fig. 2) . These features are suggestive of CXCR4 tropism.
It seemed possible that viruses that used CXCR4 less efficiently than CCR5 might have had admixtures of X4 within a majority R5 population, with the PCR-based sequences reflecting only the R5 population. In order to select for sequences predictive of CXCR4 usage, we passaged all the nine isolates that replicated to above 100 pg/ml in the initial U87.CD4.CXCR4 culture two additional times in U87.CD4. CXCR4 (a total of three passages). We extracted and amplified the DNA and analyzed the V3 sequences following selection. Isolates 96BW17A09, 03BW.1110, and 03BW.1102 showed robust replication in each passage, and their DNA could be amplified from the third round passage cells. Some changes, better predictive of CXCR4 phenotype, were noted (Fig. 2) . For 03BW.1102, the V3 loop sequence from the U87.CD4. CXCR4 cells had an overall charge of +7 due to a substitution of glutamate to glutamine at position 25. The isolate 03BW. 1110 from U87.CD4.CXCR4 cells had a dramatic change compared to PBMC derived sequences-the overall V3 loop charge increased from +4 to +7, with a serine to arginine substitution at position 11, a V3 loop crown change from GPGQ to GPGR, and a change at position 25 from aspartate to glutamine. The V3 loop sequence for 96BW17A09 remained unchanged.
Recently, Jensen et al. (2003) have described a positionspecific scoring matrices (PSSM) method for predicting coreceptor usage using V3 loop sequences. In order to test the usefulness of PSSM in comparison with other commonly used methods for efficiency in predicting coreceptor usage for HIV-1C, we assembled available coreceptor characterized subtype C sequences from our current study in Botswana, as well as from South Africa , Malawi (Ping et al., 1999) , Zimbabwe , and from Ethiopia , and used the different methodologies to analyze them (Table 4 ). The web-based tool available at http://ubik.microslu.washington.edu/computing/ pssm/ was used for this analysis. Comparison of prediction efficiency for different methodologies is summarized in Table  4 . PSSM was able to accurately predict coreceptor usage for 151 of 159 (94.97%) of the R5-tropic HIV-1C sequences. When we used the 11/25 rule, which looks for a basic amino acid at either position 11 or 25, 156 of the 159 (98.11%) R5-tropic V3 sequences were found to be correctly identified. Using the overall charge of the V3 loop, the efficiency of prediction dropped dramatically, with only 113 of 159 sequences (71.07%) being predicted as R5-tropic. In contrast, for the X4-tropic sequences, PSSM correctly predicted 16 of the available 28 (57.14%) sequences. Only 11 of 28 (39.29%) X4 sequences had a basic amino acid at either position 11 or 25, and 24 of 28 (85.71%) samples had an overall V3 charge equal to or greater than +5.
Based on the procedure described in Materials and methods, positions 7, 8, 11, 15, 16, 18, 20, 25, 27 , and 29 in the V3 loop were found to have significantly different distributions of amino acids among the R5 and non-R5 sequence sets, after Bonferroni adjustment for the 38 tests (all had P value 0.001). By the less stringent false discovery rate method of controlling false positives, all positions with P value 0.027 were significant, which included the above 10 positions plus sites 6, 9, 12, 13, 22, 24, and 31. The 17 significant positions are indicated in Fig. 3 .
Discussion
In this study, we have attempted viral isolation from PBMCs and plasma samples obtained in 2003 from 42 HIV-1-infected individuals from Botswana. Twenty-nine viral isolates were obtained from the 42 samples, which is a viral isolation success rate of 69.0%. Eleven viral isolates obtained in 1996 from HIVinfected persons from Botswana were also included in this study. These isolates were obtained by co-culturing with PBMCs from anonymous donors from North America. A direct comparison of the viral isolation success rates and replication kinetics between the 2003 and 1996 sample sets is complicated by the different culture conditions used to isolate virus for the two sample sets and by the fact that viral load and CD4 cell counts were not available for the 1996 samples. Although only surprisingly few studies have systematically examined the ease of viral isolation of HIV-1 from diverse human populations at different stages of HIV infection and disease, we find that our success rate is well within the range of 39% to 98% previously reported for Ugandan, Brazilian, Thai, Rwandese, and North American populations (Burke et al., 1990; Ichimura et al., 1994; Rubsamen-Waigmann et al., 1994) . However, it is worth noting that, although the isolation rate appears to be within the range observed in other studies, a significant proportion of the 2003 viral isolates studied Fig. 1 . Phylogenetic tree analysis of the HIV-1 sequences. The tree was generated by the neighbor-joining method. Corrections were made for multiple substitutions, and reliability of the branching pattern was estimated by bootstraping (bootstrap values higher than 80 were considered significant and are shown in the figure) . The analyzed region of HIV-1 env (957 nucleotides) corresponds to HXB2 positions from 6858 to 7815. The reference sequences for different HIV-1 groups and subtypes were obtained from the HIV database at http://hiv-web.lanl.gov. All the Botswana sequences clustered with subtype C reference sequences, including 54 viral sequences from 1996 to 2000 and 38 sequences dated 2003. The HIV-1C lineages supported by significant bootstrap values are shown. Lineages #3, #13, and #15 include fewer viral sequences than those for which near full-length genome analysis was previously performed and are shown with asterisks. A potentially new lineage formed by 03BW.1017 and 03BW.1103 isolates was supported by a bootstrap value of 96. displayed poor replication kinetics in PBMCs. It is unclear whether this is a property attributable to the subtype C viruses or to donor PBMCs used in the isolation experiments. Other factors that could result in differences in viral replication include the percentages of CD4+ T cells in each PBMC culture, the presence of CD8+ cells in cultures, which can suppress HIV replication (and inhibit isolation), the presence of inhibitory chemokines or cytokines, and other factors. The possible contribution of these factors was beyond the scope of this study. Furthermore, differences in CCR5 expression levels as well as CCR5 cellular density are factors known to affect the efficiency of R5 virus replication (Lin et al., 2002) . Host factors not withstanding, in light of reports suggesting that HIV-1C may replicate poorly in CD4+ T lymphocytes and monocyte-derived macrophages (Bjorndal et al., 1999) , our study further adds to the need for a comprehensive analysis of replication kinetics and fitness of diverse HIV-1 strains in different host cell types and cellular environments.
Contrary to reports from elsewhere of emerging CXCR4-tropic HIV-1C isolates, we did not identify a single isolate that was only tropic for CXCR4 from our study population. Three isolates were clearly dualtropic, and they used CXCR4 more efficiently in our assay than they did CCR5. All the other isolates showed either inefficient replication or no replication in U87.CD4.CXCR4 cells. We did not find usage of coreceptors other than CCR5 and CXCR4 by HIV-1C isolates. It is important to point out that our study population had not received antiretroviral drugs, while in at least one report that observed high frequency of HIV-1C X4 variants, the study population had received antiretroviral drug treatment . Further studies of viral phenotype changes may be necessary as antiretroviral drug access becomes widespread in heavily affected regions.
The results here reinforce the observations that usage of coreceptors other than CCR5 by HIV-1C is rare and may also suggest that, even with an evolution towards X4-tropism, most HIV-1C viruses are constrained to maintain CCR5 tropism. We clearly do not know the biological properties underlying low frequency coreceptor switch for this subtype, but a structural constraint within subtype C envelope may be responsible. One may also speculate that there is low or reduced cellular expression of the CXCR4 chemokine receptor in a sub-Saharan African population such as Botswana's, where HIV-1C predominates, resulting in limited cellular targets for X4 variants. However, we have preliminary evidence that CXCR4 expression is higher than CCR5 expression in Botswana, suggesting that CXCR4 expression is not the limiting factor for HIV-1C coreceptor switch. Fig. 2 . Amino acid alignment of the V3 loop sequences of the Botswana sequences. The alignment of all available sequences from Botswana was done using ClustalX version 1.81. Gaps were introduced to maintain alignment and avoid frameshifts where possible. Dots under the consensus sequences indicate deletions and a dash represents conserved residues. For the dualtropic sequences, both the sequences obtained directly from patient PBMC and sequence obtained from third-passage U87.CD4.CXCR4 cells (marked with asterisks) are shown. Sample 03BW.6274 (highlighted) was unique in that, although the virus showed weak CXCR4 tropism in initial U87.CD4.CXCR4 culture, it failed to replicate upon passage in these cells. The isolate induced mild syncytia in MT-2 cells.
We also investigated differences between the R5 and X4 sequences of HIV-1C and particularly the efficiency of coreceptor usage prediction based on envelope V3 loop sequence. We found that, while the traditional method of looking for a basic amino acid at position 11 or 25 is very efficient for identifying CCR5 tropic sequences, it performed poorly in identifying CXCR4 variants (98% versus 39%) for subtype C viruses. Similarly, the newly described PSSM methodology using the subtype B algorithm was efficient in identifying R5 variants but not X4 variants (95% versus 57%) of HIV-1C. The overall V3 loop charge method was the best for predicting X4 usage for subtype C sequences (86%), but it did not perform as well for R5 tropic sequence prediction (71%). It should be noted that these methodologies were principally designed for subtype B sequences, and our work suggests that the methods may need to be adjusted and optimized for analysis of HIV-1 subtype C and other subtypes which form the bulk of the HIV-1 pandemic. In particular, comparison of V3 loop sequences by the amino acids at the 17 ''signature'' positions identified in this study may be useful for predicting R5 versus non-R5 phenotype for subtype C. These positions may serve as important clues for guiding the design of mutagenesis studies to study genetic determinants of coreceptor utilization and switching. Overall V3 loop charge (Fouchier et al., 1992) Charge ! +5 predicts X4/si phenotype, < +5 predicts R5/NSI phenotype 71.07% 85.71%
PSSM score method (Jensen et al., 2003) High PSSM score predicts X4 usage, low score predicts R5 usage 94.97% 57.14% a A total of 159 HIV-1 subtype C sequences from Botswana, Malawi, Zimbabwe, South Africa, and Ethiopia with documented coreceptor usage were included in analysis. Over the last several years, there has been an increasing body of evidence to suggest that HIV-1C is unique in its coreceptor usage and replication kinetics in diverse cell types. It has been difficult, however, to put together all the studies on HIV-1C and come up with an overriding theme on the biology of HIV-1 subtype C in vitro or the clinical outcome of infection in its human host, relative to other subtypes. On the one hand, it is now well established that the use of the chemokine receptor CXCR4 by HIV-1C is very rare, in contrast to subtype B viruses where the use of CXCR4 is common particularly in late stages of clinical disease. The scarcity of X4 variants among HIV-1C raises questions of whether subtype C infections are associated with delayed progression and/or a less aggressive disease course since appearance of X4 variants has been associated with faster disease progression or clinical deterioration of AIDS patients (Connor et al., 1997; Koot et al., 1992; Richman and Bozzette, 1994; Tersmette et al., 1989b) . However, when normalized for CD4 cell counts, plasma viral loads for people infected with HIV-1C are as high as or higher than for other subtypes. When HIV-1C R5 variants are compared to their subtype B counterparts, they appear to replicate less efficiently, in macrophages and PBMCs but not in dendritic and Langerhans cells (Ball et al., 2003; Pollakis et al., 2004) . It has therefore been speculated that HIV-1C is less fit and may have an attenuated phenotype, resulting possibly in a longer disease-free state for infected persons, but with sufficiently high viral loads to allow for viral transmission. Although this is an attractive model of how HIV-1C may have spread to become the predominant subtype in the pandemic, other hypotheses exist. For example, duplication of the NF-nB enhancer element in the LTR region of HIV-1C has been associated with increased responsiveness to cellular proteins and proinflammatory cytokines (Jeeninga et al., 2000; Montano et al., 1997 Montano et al., , 2000 Naghavi et al., 1999) , and this has therefore led to speculation that HIV-1C may be associated with increased replicative capacity, increased viral load, and therefore increased odds of transmission and epidemic spread. The situation is unlikely to be this simple; further studies have shown that the influence of HIV-1 LTR on replication is hostcell-dependent and is influenced by the cellular environment (van Opijnen et al., 2004) . Additionally, interpretation of replication data is complicated by the fact that cellular factors that drive viral transcription may have varied and apparently opposing effects. The effect of TNF-a is a good example: while TNF-a may preferentially upregulate HIV-1C replication by transcriptional activation via the duplicated NF-nB enhancer, this cytokine also downregulates the CCR5 chemokine receptor (Lane et al., 1999) , the main coreceptor for HIV-1C isolates, leaving unanswered questions about what the overall effect of this cytokine might be in a predominantly subtype C epidemic such as the one raging in southern Africa.
In conclusion, we have generated HIV-1C viral isolates from individuals at different stages of HIV-1C infection and studied the isolates' use of different chemokine receptors for entry into target cells. We did not detect any changes towards a higher frequency of CXCR4-tropism as the epidemic has become more established in Botswana. Further studies are needed to understand genetic changes other than coreceptor usage switch, such as increased replicative capacity, that may be associated with HIV-1C disease progression since this phenomenon has been observed in HIV-1B infections (Campbell et al., 2003) . Analysis of V3 loop sequences in this study also highlighted the limitations of the available methods for predicting coreceptor usage for HIV-1 isolates. Our study provides preliminary data for comparison with other studies. In view of the importance of the HIV-1 envelope in determining viral fitness, and as a target in both prophylactic and therapeutic interventions such as vaccines and antiviral agents, more work will be needed to address potential differences in this gene between subtypes and to understand the evolution of the subtypes that predominate in high-prevalence and incidence regions. Genetic determinants of viral fitness outside of the env gene will also need to be investigated.
Materials and methods
Sample testing
HIV testing, sample collection, PBMC isolation, and the relevant study information for the 1996 samples used in this study were described previously Novitsky et al., 2001) . For the 2003 samples, sample collection and HIV testing were done as described for the previous samples. CD4 cells were enumerated using the BD Multitest kit (CD4/CD3/CD8/CD45) on a four-parameter FACSCalibur flow cytometer (Becton Dickinson, Franklin Lakes, New Jersey, USA). Viral load was determined using the automated COBAS Amplicor/Ampli Prep HIV-1 Monitor Test V1.5 (Roche Molecular Systems Inc., Branchburg, New Jersey, USA).
Viral isolation
PBMCs were separated by density-gradient centrifugation on Lymphocyte Separation Medium (Organon Teknika, Corp., Durham, NC) or Ficoll-Paque (Amersham Biosciences, Uppsala, Sweden). 5 Â 10 6 PBMCs from three anonymous HIV-negative donors were mixed and pre-stimulated by culturing in RPMI 1640 supplemented with 10% FBS, 5 Ag/ ml phytohemagglutinin (Sigma, St. Louis, MO), and 20 U/ml of interleukin-2 (Becton Dickinson Labware, Bedford, MA) for 72 h prior to infection in a T-25 flask. To isolate virus, 2 Â 10 6
PBMCs from an HIV-positive individual were co-cultured with the stimulated HIV-negative PBMCs in the presence of 20 U/ ml of interleukin-2. Cultures were sampled and fed with 50% of replacement of the total culture volume at days 4, 7, 10, and 14. If there was no evidence of viral growth by day 14, cultures were kept up to day 21, with additional media replacement at day 18. Viral growth was monitored by quantification of p24 using the Vironostika HIV-1 Antigen Microelisa system (Biomerieux, Boxtel, Netherlands) .
For the 2003 samples, there were 5 cases where PBMCs did not yield virus and plasma was available for viral isolation. Viral isolation was therefore attempted from plasma for those 5 samples (03BW.1008, 03BW.1017, 03BW.1054, 03BW1078, and 03BW.1081). Virus isolation from plasma was attempted using the method described by Cilliers et al. (2003) . Briefly, donor PBMCs were pre-stimulated with IL-2 and PHA and then incubated overnight with 500 Al HIV-positive plasma. After 24 h, the PBMCs were washed three times with PBS and fed with fresh medium. By using this methodology, 2 isolates were generated (Table 1) .
Determination of coreceptor usage
U87.CD4 cells were obtained from the NIH AIDS Research and Reference Reagent Program (Rockville, MD). U87.CD4 cells expressing chemokine receptors CCR1, CCR2b, CCR3, CXCR4, or CCR5 were maintained in Dulbecco's modified eagle's medium (DMEM) supplemented with 15% FBS, 1 Ag/ ml puromycin, and 300 Ag/ml G418. U87.CD4 cells were cultured in the same medium but without puromycin. All the U87.CD4 cells were cultured in 6-well flat bottom plates in 2000 Al total volume of culture medium. PBMC tissue culture supernatants corresponding to 2000 pg of p24 antigen per well were used to infect U87.CD4 glioma cells that express different chemokine receptors. Sampling was done by replacing half of the culture medium at days 4 and 7.
Three proviral clones were used as positive controls-the CXCR4 tropic subtype B clone HXB2RU3, which is a derivative of HXB2 that has intact vpu, vpr, and nef genes (Ratner et al., 1987; Yu et al., 1992) , HXB2RU3CI, which is equivalent to HXB2RU3 except for the V3 loop, which has been exchanged with a CCR5-tropic V3 loop (Trujillo et al., 1996; Wang et al., 1998) , and MJ4, a CCR5-tropic subtype C clone . Subconfluent 293T cells, propagated in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS, were transfected with 8 Ag of plasmid DNA using 20 Al Lipofectamine 2000 transfection reagent (Invitrogen). Seventy-two hours post-transfection, culture supernatants were harvested and filtered through 0.45 Am-pore-size filter units (Nalgene, Rochester, NY) and HIV-1 virions were quantified by p24 antigen ELISA (Vironostika, Boston, MA). Equivalent amounts of virus (as determined by amount of p24 antigen in culture supernatant) were used to infect duplicate wells of 2 Â 10 5 U87.CD4 glioma cells with or without chemokine receptors. Twenty-four hours postinfection, cells were washed three times with phosphatebuffered saline (PBS), and fresh medium was then added. Infection of the target cells was monitored for 10 days by p24 ELISA.
Passage in U87.CD4.CXCR4 cells
All viral isolates that replicated to at least 100 pg/ml of p24 antigen in the initial U87.CD4.CXCR4 culture were passaged for 2 more rounds in fresh U87.CD4.CXCR4 cells (a total of three passages). At each round of passage, growth was monitored by p24 antigen production. At the end of the culture period, third round passage cells were lysed, DNA extracted, and PCR amplification of the HIV-1 env gene done.
Propagation in the MT-2 cell line
The MT-2 cell line was originally obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH, Dr. Douglas Richman, and was also the kind donation of Dr. Lynn Morris of the National Institute of Communicable Diseases (Johannesburg, South Africa). The cells were propagated in RPMI 1640 medium supplemented with 10% FBS in a T-25 flask. Each flask of 2 Â 10 6 cells was infected with PBMC tissue culture supernatants corresponding to 2000 pg of p24 antigen. Cultures were sampled and fed with 50% of replacement of the total culture volume at days 4, 7, 10, and 14 and cultured for a total of 21 days. The flasks were also observed under the microscope for evidence of syncytia induction. Viral growth was also monitored by quantification of p24 antigen.
DNA extraction and envelope PCR amplification
Genomic DNA was extracted directly from patients' PBMCs, PBMC co-cultures, or U87.CD4.CXCR4 cells using the QIAamp Blood kit (Qiagen, Chatsworth, CA). We used the Amplitaq Gold PCR kit (Roche Molecular Systems, Branchburg, New Jersey) to amplify a 957 basepair C2 -C5 fragment of the env gene. A nested PCR reaction protocol was used. In the first round reaction, the forward primers were vpu157 (GCA-GAAGACAGTGGCAATGA) and vpu232 (TGCTCCTT-GGGATATTGATGA), while the reverse primers were p130 (TTGATGCCCCAGACTGTGAGTT) and p131 (AGCCAG-GACTCTTGCCTGGAGCT). Four primers were used to minimize non-amplification due to primer -template mismatches. Four microliters of the first round reaction product was subjected to a second round of amplification, with the primers Bstq2+ (CCAATTCCTATACATTATTGTGC) and 1556 (CCATAGTGCTTCCTGCTGCTCCTAAGAACCCAA). Ten picomoles of each primer was used per PCR reaction. The cycling conditions for both amplifications consisted of initial activation at 95 -C for 10 min followed by 39 cycles of 94 -C for 1 min, 52 -C for 1 min, and 72 -C for 3 min. There was a final extension at 72 -C for 10 min. In cases where DNA was unavailable, amplification was attempted from plasma-extracted RNA, when available. RNA was amplified using the Titan One Tube RT-PCR kit (Roche Diagnostics Corporation, Indianapolis, IN, USA). Cycling conditions for the RT-PCR were as described above but with an initial reverse transcription step at 50 -C for 30 min. The PCR products were visualized by running a 1% agarose gel, and they were then purified using the Qiaquick PCR purification kit (Qiagen).
Sequencing and sequence analysis
The PCR product was directly sequenced on both strands using Big Dye chemistry on an ABI Prism 3100 Genetic Analyzer (Applied Biosystems, Foster City, California, USA). Individual contiguous sequences were assembled and edited using the Sequencher software program (Gene Codes Corporation, Ann Arbor, Michigan). Multiple sequence alignment was carried out using ClustalX version 1.81. Alignment was manually adjusted using BioEdit. The pairwise distances of nucleotide alignment were computed by DNADist with the Kimura two-parameter model. The neighbor-joining tree and bootstrap values were generated using TreeCon version 1.3b.
To search for ''signature positions'' that distinguish R5 from non-R5 V3 loop sequences, we assembled HIV-1C V3 loop amino acid sequences with documented coreceptor usage from current and previously published studies Johnston et al., 2003; Ping et al., 1999; Pollakis et al., 2004) . Each position in the V3 loop was examined for possible differences in the distribution of amino acid frequencies among the 159 R5 sequences and the 28 non-R5 sequences. The difference in amino acid distributions at each position i was measured using a Kullback -Leibler statistic, defined as
where the sum aa is over the 20 amino acids plus a gap character, f 1 (i, aa) is the fraction of the 28 non-R5 sequences with amino acid aa, f 2 (i, aa) is the fraction of the 159 R5 sequences with amino acid aa, n 1 = 28, n 2 = 159, and I( f 2 (i, aa) > 0) is 1 if f 2 (i, aa) = 1 and 0 otherwise. The statistic KL(i) was proposed by Wu et al. (2001) as a measurement of sequence dissimilarity and is similar to the entropy statistic (Yusim et al., 2002) . A permutation procedure was used for computing P values for each of the 38 positions. Permuted datasets were generated by randomly dividing the pooled set of 187 V3 loop sequences into two sequence sets, of sizes 28 and 159 sequences. Ten thousand permuted datasets were generated, and, for each dataset, a 2-sided P value for each position i was computed as N i /10,000, where N i is the number of the KL(i) statistics computed based on permuted datasets that equaled or exceeded the value of KL(i) computed based on the real dataset. To avoid a high rate of false positive results, it is necessary to account for the fact that 38 tests were performed. Two methods were used to correct for the multiple tests; first, the Bonferroni method was used, according to which positions with P value < 0.05/38 = 0.00132 were deemed significant; and second, the false discovery rate method was used (Benjamini and Hochberg, 1995) , which determines the set of significant positions such that fewer than 5% of these significant positions are expected to be ''false discoveries'' (i.e., erroneous findings). The statistical procedure was implemented in Fortran 90.
Genebank accession numbers
New sequences described in this study are available under GenBank accession nos. AY887852-AY887892.
